JP2014505264A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505264A5
JP2014505264A5 JP2013553610A JP2013553610A JP2014505264A5 JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5 JP 2013553610 A JP2013553610 A JP 2013553610A JP 2013553610 A JP2013553610 A JP 2013553610A JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5
Authority
JP
Japan
Prior art keywords
marker
level
determining
biological sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013553610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505264A (ja
JP5990542B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024729 external-priority patent/WO2012109592A1/en
Publication of JP2014505264A publication Critical patent/JP2014505264A/ja
Publication of JP2014505264A5 publication Critical patent/JP2014505264A5/ja
Application granted granted Critical
Publication of JP5990542B2 publication Critical patent/JP5990542B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013553610A 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法 Expired - Fee Related JP5990542B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161441785P 2011-02-11 2011-02-11
US61/441,785 2011-02-11
US201161442454P 2011-02-14 2011-02-14
US61/442,454 2011-02-14
US201161472424P 2011-04-06 2011-04-06
US61/472,424 2011-04-06
PCT/US2012/024729 WO2012109592A1 (en) 2011-02-11 2012-02-10 Methods for diagnosing systemic lupus erythematosus

Publications (3)

Publication Number Publication Date
JP2014505264A JP2014505264A (ja) 2014-02-27
JP2014505264A5 true JP2014505264A5 (show.php) 2015-04-02
JP5990542B2 JP5990542B2 (ja) 2016-09-14

Family

ID=45774332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553610A Expired - Fee Related JP5990542B2 (ja) 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法

Country Status (4)

Country Link
US (7) US10132813B2 (show.php)
EP (1) EP2673644B1 (show.php)
JP (1) JP5990542B2 (show.php)
WO (1) WO2012109592A1 (show.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10132813B2 (en) 2011-02-11 2018-11-20 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
US9863946B2 (en) 2013-02-08 2018-01-09 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
WO2014124098A1 (en) * 2013-02-08 2014-08-14 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
JP6453299B2 (ja) * 2013-03-15 2019-01-16 エグザゲン ダイアグノスティクス，インコーポレイテッド 全身性エリテマトーデスを治療および診断するための方法
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
ES2731908T3 (es) * 2014-03-13 2019-11-19 Inst Nat Sante Rech Med Métodos de diagnóstico para el lupus
EP3177930A1 (en) * 2014-08-08 2017-06-14 Allegheny-Singer Research Institute Anti-lymphocyte autoantibodies as diagnostic biomarkers
KR20180029046A (ko) 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
AU2016303499B2 (en) 2015-07-31 2020-07-02 Allegheny-Singer Research Institute Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
KR102608933B1 (ko) * 2021-10-20 2023-12-01 재단법인 아산사회복지재단 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
CN119889651B (zh) * 2024-12-24 2025-11-18 北京医院 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256708B2 (en) 1999-06-23 2007-08-14 Visicu, Inc. Telecommunications network for remote patient monitoring
ATE479707T1 (de) * 2001-09-10 2010-09-15 Univ Pittsburgh Diagnose und aufzeichnung von systemischem lupus erythematosus und von skleroderm
ATE552501T1 (de) 2003-04-16 2012-04-15 Univ Pittsburgh Identifizierung und überwachung von systemischem lupus erythematodes
WO2004112572A2 (en) 2003-06-13 2004-12-29 University Of Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
DE602005023009D1 (de) 2004-04-09 2010-09-30 Univ Pittsburgh Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
DK1745287T3 (da) 2004-05-11 2011-01-24 Univ Pittsburgh Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
AU2007235731B2 (en) 2006-04-07 2012-01-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Systems and methods for predicting an individual's risk of developing rheumatoid arthritis
EP2347259A4 (en) 2008-10-16 2012-02-29 Cypress Bioscience Inc METHOD FOR DIAGNOSIS AND MONITORING OF ILLICIT ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATODES (SLE) AND OTHER AUTOIMMUNE DISEASES
WO2011047337A2 (en) * 2009-10-16 2011-04-21 Exagen Diagnostics, Inc. Cell-based complement activation product algorithm for diagnosing systemic lupus erythematosus
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
ES2425540T3 (es) 2010-02-22 2013-10-16 Medipan Gmbh Procedimiento y dispositivo para la detección simultánea de anticuerpos unidos a sustratos sintéticos y celulares y/o tisulares
US10132813B2 (en) * 2011-02-11 2018-11-20 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
US9804156B2 (en) 2012-03-06 2017-10-31 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
JP6453299B2 (ja) 2013-03-15 2019-01-16 エグザゲン ダイアグノスティクス，インコーポレイテッド 全身性エリテマトーデスを治療および診断するための方法

Similar Documents

Publication Publication Date Title
JP2014505264A5 (show.php)
Mandaliya et al. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
Salumets et al. Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood
Bizzaro et al. Are we at a stage to predict autoimmune rheumatic diseases?
Jansen et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities
Demoruelle et al. Performance of anti–cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease
Robinson et al. Biomarkers to guide clinical therapeutics in rheumatology?
Didier et al. Immune correlates of aging in outdoor-housed captive rhesus macaques (Macaca mulatta)
US20140315742A1 (en) Biodosimetry panels and methods
Walzl et al. Biomarkers for TB treatment response: challenges and future strategies
Grauer et al. Neurocognitive decline in HIV patients is associated with ongoing T‐cell activation in the cerebrospinal fluid
High et al. Translational research in immune senescence: assessing the relevance of current models
Vos et al. The 2000HIV study: Design, multi-omics methods and participant characteristics
Paczesny Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’biomarker
Bonavia et al. Comparison of rapid cytokine immunoassays for functional immune phenotyping
Lanzillo et al. JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
CN119534864B (zh) 一种新型的IgG4相关性疾病的标志物及其应用
Zingaropoli et al. JC virus‐DNA detection is associated with CD8 effector accumulation in peripheral blood of patients with multiple sclerosis under natalizumab treatment, independently from JC virus serostatus
JP2017528734A5 (show.php)
Drabe et al. Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo: SOT study): a prospective non-interventional observational trial
CN119889651B (zh) 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法
Barnes et al. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis
Manzano-Román et al. Protein arrays as tool for studies at the host–pathogen interface
RU2017107273A (ru) Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров
CN119626506A (zh) 一种系统性红斑狼疮活动性评估模型的构建方法及其应用